Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mesoblast Limited ( (AU:MSB) ) has provided an update.
Mesoblast Limited announced the U.S. commercial launch of Ryoncil®, the first FDA-approved mesenchymal stromal cell therapy for treating pediatric steroid-refractory acute graft-versus-host disease. With successful financing of $160 million, Mesoblast is well-positioned to execute the launch, expand clinical indications, and meet projected demand. The company has established a distribution network and patient access programs to facilitate the therapy’s availability and plans a strategic rollout targeting key treatment centers. This launch signifies a significant step in addressing unmet medical needs and solidifying Mesoblast’s presence in the cellular therapy industry.
More about Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines focusing on treating inflammatory diseases. The company offers off-the-shelf cellular therapies, including Ryoncil® for pediatric steroid-refractory acute graft-versus-host disease, and is exploring a broad market potential in heart failure and chronic low back pain.
YTD Price Performance: 13.86%
Average Trading Volume: 130,658
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.29B
Learn more about MSB stock on TipRanks’ Stock Analysis page.
